Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $48.83 billion. The enterprise value is $61.74 billion.
| Market Cap | 48.83B |
| Enterprise Value | 61.74B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.17 billion shares outstanding. The number of shares has increased by 2.12% in one year.
| Current Share Class | 1.17B |
| Shares Outstanding | 1.17B |
| Shares Change (YoY) | +2.12% |
| Shares Change (QoQ) | +1.55% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 78.04% |
| Float | 1.09B |
Valuation Ratios
The trailing PE ratio is 98.04 and the forward PE ratio is 14.61. Teva Pharmaceutical's PEG ratio is 2.00.
| PE Ratio | 98.04 |
| Forward PE | 14.61 |
| PS Ratio | 2.83 |
| Forward PS | 2.86 |
| PB Ratio | 6.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 39.54 |
| P/OCF Ratio | 27.59 |
| PEG Ratio | 2.00 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.02, with an EV/FCF ratio of 50.00.
| EV / Earnings | 122.03 |
| EV / Sales | 3.58 |
| EV / EBITDA | 14.02 |
| EV / EBIT | 18.05 |
| EV / FCF | 50.00 |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 2.13.
| Current Ratio | 0.95 |
| Quick Ratio | 0.51 |
| Debt / Equity | 2.13 |
| Debt / EBITDA | 3.75 |
| Debt / FCF | 13.76 |
| Interest Coverage | 4.30 |
Financial Efficiency
Return on equity (ROE) is 6.65% and return on invested capital (ROIC) is 16.33%.
| Return on Equity (ROE) | 6.65% |
| Return on Assets (ROA) | 5.35% |
| Return on Invested Capital (ROIC) | 16.33% |
| Return on Capital Employed (ROCE) | 13.89% |
| Weighted Average Cost of Capital (WACC) | 7.44% |
| Revenue Per Employee | $507,511 |
| Profits Per Employee | $14,904 |
| Employee Count | 33,950 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.47 |
Taxes
| Income Tax | -136.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.95% in the last 52 weeks. The beta is 0.82, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +103.95% |
| 50-Day Moving Average | 39.33 |
| 200-Day Moving Average | 34.73 |
| Relative Strength Index (RSI) | 59.10 |
| Average Volume (20 Days) | 7,132,346 |
Short Selling Information
The latest short interest is 28.07 million, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 28.07M |
| Short Previous Month | 31.48M |
| Short % of Shares Out | 2.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.40 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $17.23 billion and earned $506.00 million in profits. Earnings per share was $0.43.
| Revenue | 17.23B |
| Gross Profit | 9.22B |
| Operating Income | 3.42B |
| Pretax Income | 371.00M |
| Net Income | 506.00M |
| EBITDA | 4.41B |
| EBIT | 3.42B |
| Earnings Per Share (EPS) | $0.43 |
Balance Sheet
The company has $4.09 billion in cash and $17.00 billion in debt, with a net cash position of -$12.91 billion or -$11.07 per share.
| Cash & Cash Equivalents | 4.09B |
| Total Debt | 17.00B |
| Net Cash | -12.91B |
| Net Cash Per Share | -$11.07 |
| Equity (Book Value) | 7.98B |
| Book Value Per Share | 6.84 |
| Working Capital | -823.00M |
Cash Flow
In the last 12 months, operating cash flow was $1.77 billion and capital expenditures -$535.00 million, giving a free cash flow of $1.24 billion.
| Operating Cash Flow | 1.77B |
| Capital Expenditures | -535.00M |
| Depreciation & Amortization | 985.00M |
| Net Borrowing | -61.00M |
| Free Cash Flow | 1.24B |
| FCF Per Share | $1.06 |
Margins
Gross margin is 53.51%, with operating and profit margins of 19.85% and 2.94%.
| Gross Margin | 53.51% |
| Operating Margin | 19.85% |
| Pretax Margin | 2.15% |
| Profit Margin | 2.94% |
| EBITDA Margin | 25.57% |
| EBIT Margin | 19.85% |
| FCF Margin | 7.17% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.12% |
| Shareholder Yield | -2.12% |
| Earnings Yield | 1.02% |
| FCF Yield | 2.53% |
Analyst Forecast
The average price target for Teva Pharmaceutical is $48.94, which is 16.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $48.94 |
| Price Target Difference | 16.94% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 1.58% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.96 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.96 |
| Piotroski F-Score | 7 |